

DAFTAR PUSTAKA

1. Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. *Intensive Care Med.* 2021;47(11):1181–247.
2. Seymour CW, Liu VX, Iwashyna TJ, Brunkhorst FM, Rea TD, Scherag A, et al. Assessment of Clinical Criteria for Sepsis. *JAMA.* 2016;315(8):762–74.
3. Lin J, Gu C, Zhang S, Tian L, Ren K, Cao Z, et al. Sites and Causes of Infection in Patients with Sepsis-Associated Liver Dysfunction: A Population Study from the Medical Information Mart for Intensive Care III. *Med Sci Monit Int Med J Exp Clin Res.* 2021;27:e928928-1-10.
4. Nessler N, Launey Y, Aninat C, Morel F, Mallédant Y, Seguin P. Clinical review: The liver in sepsis. *Crit Care Lond Engl.* 2012;16(5):235.
5. Tanaka S, Tymowski CD, Stern J, Bouzid D, Zappella N, Snauwaert A, et al. Relationship between liver dysfunction, lipoprotein concentration and mortality during sepsis. *PLOS ONE.* 2022;17(8):e0272352.
6. Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic Inflammatory Response Syndrome Criteria in Defining Severe Sepsis. *N Engl J Med.* 2015;372(17):1629–38.
7. Kramer L, Jordan B, Druml W, Bauer P, Metnitz PGH. Incidence and prognosis of early hepatic dysfunction in critically ill patients—A prospective multicenter study; *Crit Care Med.* 2007;35(4):1099–e7.
8. Rudd KE, Johnson SC, Agesa KM, Shackelford KA, Tsoi D, Kievlan DR, et al. Global, regional, and national sepsis incidence and mortality, 1990–2017: analysis for the Global Burden of Disease Study. *The Lancet.* 2020;395(10219):200–11.
9. Yan J, Li S, Li S. The role of the liver in sepsis. *Int Rev Immunol.* 2014;33(6):498–510.
10. Woźnica EA, Inglot M, Woźnica RK, Łysenko L. Liver dysfunction in sepsis. *Adv Clin Exp Med Off Organ Wroclaw Med Univ.* 2018:547–51.

11. Fadrian F, Linosefa L, Ridhwan FM, Hasnah H, Syafa AA. Multidrug-resistant organisms and determinant factors in sepsis patients. *Iranian Journal of medical microbiology*.2023;17(5):10.
12. The EPISEPSIS Study Group. EPISEPSIS: a reappraisal of the epidemiology and outcome of severe sepsis in French intensive care units. *Intensive Care Med*. 2004;30(4):580–8.
13. Ghenu MI, Dragoş D, Manea MM, Ionescu D, Negreanu L. Pathophysiology of sepsis-induced cholestasis: A review. *JGH Open Open Access J Gastroenterol Hepatol*. 2022;6(6):378–87.
14. Waseem N, Chen PH. Hypoxic Hepatitis: A Review and Clinical Update. *J Clin Transl Hepatol*. 2016;4(3):263–8.
15. Woźnica E, Łysenko L. Procalcitonin in liver dysfunction — Dr Jekyll or Mr Hyde? *Anestezjol Intensywna Ter*. 2018;50(3):226–9.
16. Niesobska EW, Lesnik P, Woznica R, Janc J, Zalewska M, Lysenko L. The role of Plasminogen Activator Inhibitor 1 in predicting sepsis-associated liver dysfunction: an observational study. *In Review*; 2021:1-20.
17. Van den broecke A, Van Coile L, Decruyenaere A, Colpaert K, Benoit D, Van Vlierberghe H, et al. Epidemiology, causes, evolution and outcome in a single-center cohort of 1116 critically ill patients with hypoxic hepatitis. *Ann Intensive Care*. 2018;8:15.
18. Hall P, Cash J. What is the Real Function of the Liver ‘Function’ Tests? *Ulster Med J*. 2012;81(1):30–6.
19. Patel JJ, Taneja A, Niccum D, Kumar G, Jacobs E, Nanchal R. The Association of Serum Bilirubin Levels on the Outcomes of Severe Sepsis. *J Intensive Care Med*. 2015;30(1):23–9.
20. Wang D, Yin Y, Yao Y. Advances in sepsis-associated liver dysfunction. *Burns Trauma*. 2014;2(3):97–105.
21. Canabal JM, Kramer DJ. Management of sepsis in patients with liver failure: *Curr Opin Crit Care*. 2008;14(2):189–97.
22. Lee Y, Friedman SL. Fibrosis in the Liver. In: *Progress in Molecular Biology and Translational Science*. Elsevier; 2010:151–200.

23. Takagi T, Suzuki R, Sugimoto M, Konno N, Sato Y, Irie H, et al. Non-specific elevation of serum Mac-2 binding protein glycosylation isomer levels in patients with biliary disease. *Mol Clin Oncol*. 2019;10(1):168–72.
24. Dechêne A, Sowa JP, Gieseler RK, Jochum C, Bechmann LP, El Fouly A, et al. Acute liver failure is associated with elevated liver stiffness and hepatic stellate cell activation. *Hepatology*. 2010;52(3):1008–16.
25. He Y, Jin L, Wang J, Yan Z, Chen T, Zhao Y. Mechanisms of fibrosis in acute liver failure. *Liver Int*. 2015;35(7):1877–85.
26. Hashimoto E, Kwo PY, Suriawinata AA, Tsui WMS, Iwai M, editors. *Diagnosis of Liver Disease*. Singapore: Springer Singapore; 2019:24-5.
27. Xu H, Kong W, Liu L, Chi X, Wang X, Wu R, et al. Accuracy of M2BPGi, compared with Fibro Scan®, in analysis of liver fibrosis in patients with hepatitis C. *BMC Gastroenterol*. 2017;17(1):62.
28. Kuno A, Ikehara Y, Tanaka Y, Ito K, Matsuda A, Sekiya S, et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. *Sci Rep*. 2013;3(1):1065.
29. Liu CH, Liu CJ, Su TH, Huang SC, Tseng TC, Wu JH, et al. Serum Mac-2 Binding Protein Glycosylation Isomer to Predict the Severity of Hepatic Fibrosis in Patients with Hepatitis C Virus Infection. *Diagnostics*. 2022;12(11):2650.
30. Bekki Y, Yoshizumi T, Shimoda S, Itoh S, Harimoto N, Ikegami T, et al. Hepatic stellate cells secreting WFA⁺-M2BP: Its role in biological interactions with Kupffer cells: HSCs secreting M2BPGi. *J Gastroenterol Hepatol*. 2017;32(7):1387–93.
31. Shirabe K, Bekki Y, Gantumur D, Araki K, Ishii N, Kuno A, et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. *J Gastroenterol*. 2018;53(7):819–26.
32. Saleh SA, Salama MM, Alhousseini MM, Mohamed GA. M2BPGi for assessing liver fibrosis in patients with hepatitis C treated with direct-acting antivirals. *World J Gastroenterol*. 2020;26(21):2864–76.

33. Seike T, Komura T, Shimizu Y, Omura H, Kumai T, Kagaya T, et al. The Serum Mac-2-binding Protein Glycosylation Isomer Dynamics in Acute Liver Injury. *Intern Med.* 2020;59(13):1581–8.
34. Morio K, Imamura M, Daijo K, Teraoka Y, Honda F, Nakamura Y, et al. Wisteria floribunda agglutinin positive Mac-2-binding protein level increases in patients with acute liver injury. *J Gastroenterol.* 2017;52(12):1252–7.
35. The Ochanomizu Liver Conference Study Group, Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, et al. Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy. *Hepato Int.* 2016;10(6):956–64.
36. Kasper P, Tacke F, Steffen HM, Michels G. Leberfunktionsstörungen bei Sepsis. *Med Klin - Intensivmed Notfallmedizin.* 2020;115(7):609–19.
37. Sauer M, Doß S, Ehler J, Mencke T, Wagner NM. Procalcitonin Impairs Liver Cell Viability and Function In Vitro: A Potential New Mechanism of Liver Dysfunction and Failure during Sepsis? *BioMed Res Int.* 2017;2017:6130725.
38. Sarin SK, Choudhury A, Sharma MK, Maiwall R, Al Mahtab M, Rahman S, et al. Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update. *Hepato Int.* 2019;13(4):353–90.
39. Qu J, Feng P, Luo Y, Lü X. Impact of hepatic function on serum procalcitonin for the diagnosis of bacterial infections in patients with chronic liver disease. *Medicine (Baltimore).* 2016;95(30):e4270.
40. Vincent JL, Angus DC, Artigas A, Kalil A, Basson BR, Jamal HH, et al. Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial*: *Crit Care Med.* 2003;31(3):834–40.
41. Beyer D, Hoff J, Sommerfeld O, Zipprich A, Gaßler N, Press AT. The liver in sepsis: molecular mechanism of liver failure and their potential for clinical translation. *Mol Med.* 2022;28:84.

42. Sun J, Zhang J, Wang X, Ji F, Ronco C, Tian J, et al. Gut-liver crosstalk in sepsis-induced liver injury. *Crit Care*. 2020;24(1):614.
43. Schaarschmidt B, Vlaic S, Medyukhina A, Neugebauer S, Nietzsche S, Gonnert FA, et al. Molecular signatures of liver dysfunction are distinct in fungal and bacterial infections in mice. *Theranostics*. 2018;8(14):3766–80.
44. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest*. 2005;115(2):209–18.
45. Horvatits T, Drolz A, Trauner M, Fuhrmann V. Liver Injury and Failure in Critical Illness. *Hepatology*. 2019;70(6):2204–15.
46. Strnad P, Tacke F, Koch A, Trautwein C. Liver — guardian, modifier and target of sepsis. *Nat Rev Gastroenterol Hepatol*. 2017 Jan;14(1):55–66.
47. Heymann F, Tacke F. Immunology in the liver — from homeostasis to disease. *Nat Rev Gastroenterol Hepatol*. 2016;13(2):88–110.
48. Jenniskens M, Langouche L, Vanwijngaerden YM, Mesotten D, Van den Berghe G. Cholestatic liver (dys)function during sepsis and other critical illnesses. *Intensive Care Med*. 2016;42(1):16–27.
49. Bernal W. The liver in systemic disease: Sepsis and critical illness. *Clin Liver Dis*. 2016;7(4):88–91.
50. Li J, Zhao YR, Tian Z. Roles of hepatic stellate cells in acute liver failure: From the perspective of inflammation and fibrosis. *World J Hepatol*. 2019;11(5):412–20.
51. Iredale J, Campana L. Regression of Liver Fibrosis. *Semin Liver Dis*. 2017;37(1):1.
52. Ciobanu AO, Gherasim L. Ischemic Hepatitis – Intercorrelated Pathology. *Mædica*. 2018;13(1):5–11.
53. Kobashi H, Toshimori J, Yamamoto K. Sepsis-associated liver injury: Incidence, classification and the clinical significance: Sepsis-associated liver injury. *Hepatol Res*. 2013;43(3):255–66.
54. Hentschel F, Bornscheuer T, Lüth S. Sekundär sklerosierende Cholangitis bei kritisch Kranken. *Z Für Gastroenterol*. 2019;57(08):977–82.
55. Worapratya P, Wuthisuthimethawee P. Septic shock in the ER: diagnostic and management challenges. *Open Access Emerg Med OAEM*. 2019;11:77– 86.

56. Lie K, Lau CY, Vinh Chau N, West E, Limmathurotsakul D. Utility of SOFA score, management and outcomes of sepsis in Southeast Asia: A multinational multicenter prospective observational study. *J Intensive Care*. 2018;6(9):1-8.
57. Aryabiantara IW, Wiryana M, Sinardja K, Agung Senapathi TG, Widnyana IMG, Surya Panji PA, et al. Comparative Validity Sequential Scoring System Organ Failure Assesment (SOFA) and Quick - Sequential Organ Failure Assesment (qSOFA) on Estimating Mortality for Patients Treated in the Intensive Care Unit of Sanglah General Hospital. *J Aging Sci*. 2017;8(5):1-5.
58. Baudi I, Inoue T, Tanaka Y. Novel Biomarkers of Hepatitis B and Hepatocellular Carcinoma: Clinical Significance of HBcrAg and M2BPGi. *Int J Mol Sci*. 2020;21(3):949.
59. Kagawa T, Tsuruno C, Takahama Y, Int'l SJ. Development of a Novel Clinical Diagnostic Method for the Detection of Glycosylation Changes in Liver Fibrosis. 2015;25(1):1-5.
60. Ito K, Murotani K, Nakade Y, Inoue T, Nakao H, Sumida Y, et al. Serum *Wisteria floribunda* agglutinin-positive Mac-2-binding protein levels and liver fibrosis: A meta-analysis: WFA+-M2BP and liver fibrosis. *J Gastroenterol Hepatol*. 2017;32(12):1922–30.
61. Tamaki N, Kurosaki M, Loomba R, Izumi N. Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. *Ann Lab Med*. 2021;41(1):16–24.
62. Kikukawa K, Uchida-Kobayashi S, Tamori A, Yoshida K, Kotani K, Motoyama H, et al. Serum Mac-2-binding protein glycosylation isomer predicts esophagogastric varices in cirrhotic patients with chronic hepatitis C virus infection treated with IFN-free direct-acting antiviral agent: M2BPGi levels predict varices in SVR patients. *Ann Hepatol*. 2020;19(4):367–72.
63. Wang L, Guo XL. Molecular regulation of galectin-3 expression and therapeutic implication in cancer progression. *Biomed Pharmacother*. 2016;78:165–71.

64. Dolgormaa G, Harimoto N, Ishii N, Yamanaka T, Hagiwara K, Tsukagoshi M, et al. Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling. *Br J Cancer*. 2020;123(7):1145–53.
65. Mak LY, Wong DKH, Cheung KS, Seto WK, Lai CL, Yuen MF. Role of serum M2BPGi levels on diagnosing significant liver fibrosis and cirrhosis in treated patients with chronic hepatitis B virus infection. *Clin Transl Gastroenterol*. 2018;9(6):163.
66. Nishikawa H, Enomoto H, Iwata Y, Kishino K, Shimono Y, Hasegawa K, et al. Serum *Wisteria floribunda* agglutinin-positive Mac-2-binding protein for patients with chronic hepatitis B and C: a comparative study. *J Viral Hepat*. 2016;23(12):977–84.
67. Umemura T, Joshita S, Sekiguchi T, Usami Y, Shibata S, Kimura T, et al. Serum *Wisteria floribunda* Agglutinin-Positive Mac-2-Binding Protein Level Predicts Liver Fibrosis and Prognosis in Primary Biliary Cirrhosis. *Am J Gastroenterol*. 2015;110.
68. Umetsu S, Inui A, Sogo T, Komatsu H, Fujisawa T. Usefulness of serum *Wisteria floribunda* agglutinin-positive Mac-2 binding protein in children with primary sclerosing cholangitis: WFA⁺-M2BP in pediatric PSC. *Hepatol Res*. 2018;48(5):355–63.
69. Kono M, Nakamura Y, Oyama Y, Mori K, Hozumi H, Karayama M, et al. Increased levels of serum *Wisteria floribunda* agglutinin-positive Mac-2 binding protein in idiopathic pulmonary fibrosis. *Respir Med*. 2016;115:46–52.
70. Fujiyama T, Ito T, Ueda K, Tachibana Y, Yasunaga K, Miki M, et al. Serum levels of *Wisteria floribunda* agglutinin-positive Mac-2 binding protein reflect the severity of chronic pancreatitis. *J Dig Dis*. 2017;18(5):302–8.
71. Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, et al. Idiopathic pulmonary fibrosis. *Nat Rev Dis Primer*. 2017 Dec 21;3(1):17074.
72. Singh VK, Yadav D, Garg PK. Diagnosis and Management of Chronic Pancreatitis: A Review. *JAMA*. 2019;322(24):2422.

73. Waragai Y, Suzuki R, Takagi T, Sugimoto M, Asama H, Watanabe K, et al. Clinical significance of serum *Wisteria floribunda* agglutinin-positive Mac-2 binding protein in pancreatic ductal adenocarcinoma. *Pancreatology*. 2016;16(6):1044–50.
74. Fusco O, Querzoli P, Nenci I, Natoli C, Brakebush C, Ullrich A, et al. 90K (Mac-2 BP) gene expression in breast cancer and evidence for the production of 90K by peripheral-blood mononuclear cells. *Int J Cancer*. 1998;79(1):23–6.
75. Iacobelli S, Sismondi P, Giai M, D'Egidio M, Tinari N, Amatetti C, et al. Prognostic value of a novel circulating serum 90K antigen in breast cancer. *Br J Cancer*. 1994;69(1):172–6.
76. Koyama Y, Brenner D. Liver inflammation and fibrosis. *J Clin Invest*. 2017;127(1):172–6.
77. Depkes RI. Klasifikasi umur menurut kategori. Ditjen Yankes.2009.
78. Liu C, Suo S, Luo L, Chen X, Ling C, Cao S. SOFA Score in relation to Sepsis: Clinical Implications in Diagnosis, Treatment, and Prognostic Assessment. *Comput Math Methods Med*. 2022;2022:7870434.
79. Emiliana W. Sirosis hepatis child pugh class C dengan komplikasi asites grade III dan hiponatremia. *J Medula*. 2013;1(05):51–7.
80. Cho EJ, Jung GC, Kwak MS, Yang JI, Yim JY, Yu SJ, et al. Fatty Liver Index for Predicting Nonalcoholic Fatty Liver Disease in an Asymptomatic Korean Population. *Diagnostics*. 2021;11(12):2233.
81. Fortea JI, Puente Á, Cuadrado A, Huelin P, Pellón R, González Sánchez FJ, et al. Congestive Hepatopathy. *Int J Mol Sci*. 2020;21(24):9420.
82. Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR. ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury. *Am J Gastroenterol*. 2021;116(5):878–98.
83. Kim BSM, Li BT, Engel A, Samra JS, Clarke S, Norton ID, et al. Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. *World J Gastrointest Pathophysiol*. 2014;5(4):467–78.

84. Xie T, Xin Q, Cao X, Chen R, Ren H, Liu C, et al. Clinical characteristics and construction of a predictive model for patients with sepsis related liver injury. *Clin Chim Acta*. 2022;537:80–6.
85. Lakbar I, Einav S, Lalevée N, Martin-Loeches I, Pastene B, Leone M. Interactions between Gender and Sepsis—Implications for the Future. *Microorganisms*. 2023;11(3):746.
86. Klein SL, Flanagan KL. Sex differences in immune responses. *Nat Rev Immunol*. 2016;16(10):626–38.
87. Clifford KM, Dy-Boarman EA, Haase KK, Maxvill K (Hesch), Pass S, Alvarez CA. Challenges with Diagnosing and Managing Sepsis in Older Adults. *Expert Rev Anti Infect Ther*. 2016;14(2):231–41.
88. Liu Y, Sun R, Jiang H, Liang G, Huang Z, Qi L, et al. Development and validation of a predictive model for in-hospital mortality in patients with sepsis-associated liver injury. *Ann Transl Med*. 2022;10(18):997.
89. Cui L, Bao J, Yu C, Zhang C, Huang R, Liu L, et al. Development of a nomogram for predicting 90-day mortality in patients with sepsis-associated liver injury. *Sci Rep*. 2023;13:3662.
90. Jang SY, Tak WY, Park SY, Kweon YO, Lee YR, Kim G, et al. Diagnostic Efficacy of Serum Mac-2 Binding Protein Glycosylation Isomer and Other Markers for Liver Fibrosis in Non-Alcoholic Fatty Liver Diseases. *Ann Lab Med*. 2021;41(3):302–9.
91. Haryono H, Bestari MB, Agustanti N, Girawan D, Wahyudi Y, Abdurachman SA, et al. Correlation of Mac-2 Binding Protein Glycosylation Isomer (M2BPGi) with Liver Transient Elastography Results in Evaluating Liver Fibrosis in Chronic Hepatitis B Patients. *Indones J Gastroenterol Hepatol Dig Endosc*. 2023;24(1):12–22.
92. Nishikawa H, Enomoto H, Iwata Y, Hasegawa K, Nakano C, Takata R, et al. Clinical significance of serum *Wisteria floribunda* agglutinin positive Mac-2-binding protein level and high-sensitivity C-reactive protein concentration in autoimmune hepatitis. *Hepatol Res*. 2016;46(7):613–21.
93. Chauhan A, Adams DH, Watson SP, Lalor PF. Platelets: No longer bystanders in liver disease. *Hepatology*. 2016;64(5):1774–84.

94. Zhao H, Huang H, Alam A, Chen Q, Suen K, Cui J, et al. VEGF mitigates histone induced pyroptosis in remote liver injury associated with renal allograft ischemia reperfusion injury in rats. *AJT*.2018;18(8):1890-1903.

